Urolithin A occupies an unusual position in the supplement landscape: it is one of the very few compounds in this category that has been tested in randomised, double-blind, placebo-controlled trials with clinically meaningful endpoints. This matters because the supplement industry is saturated with products that extrapolate from in vitro or animal data to human benefit claims. Urolithin A's clinical programme, led largely by researchers at the École Polytechnique Fédérale de Lausanne (EPFL) and subsequently by Amazentis, provides a more rigorous evidence base than most.
What Is Urolithin A?
Urolithin A is a postbiotic compound produced when gut bacteria metabolise ellagitannins — polyphenols found in pomegranates, walnuts, and certain berries. The conversion is highly variable between individuals: studies suggest that only 30–40% of the population produces meaningful amounts of Urolithin A from dietary sources, which is why direct supplementation has attracted interest.
Its primary mechanism of action is the activation of mitophagy — the selective autophagy process by which cells identify and remove damaged or dysfunctional mitochondria. By clearing this cellular debris, Urolithin A supports the renewal of the mitochondrial network and, in theory, improves the overall efficiency of cellular energy production.
The NOURISH Trial: Key Findings
The most important clinical study to date is the NOURISH trial (Singh et al., Cell Reports Medicine, 2022), a four-month randomised, double-blind, placebo-controlled trial in 88 healthy adults aged 40–64. Participants received either 500mg of Urolithin A daily or placebo. The primary endpoints were muscle strength and endurance capacity.
| Endpoint | Urolithin A (500mg) | Placebo | Statistical Significance |
|---|---|---|---|
| Hamstring muscle strength | +12.0% | +1.0% | p < 0.05 |
| Knee flexion strength | +10.6% | +0.2% | p < 0.05 |
| 6-minute walk distance | +8.4% | +0.2% | p < 0.05 |
| Plasma acylcarnitines (mitochondrial biomarker) | Significant reduction | No change | p < 0.01 |
| Adverse events | None reported | None reported | — |
The reduction in plasma acylcarnitines is particularly significant from a mechanistic standpoint. Elevated acylcarnitines are a biomarker of impaired mitochondrial fatty acid oxidation — their reduction indicates improved mitochondrial metabolic efficiency, not merely a symptomatic effect.
The Dose Question
The NOURISH trial used 500mg of Urolithin A daily. This is an important detail because many commercially available formulations contain lower doses — sometimes as low as 250mg — which fall below the threshold at which clinical benefits were demonstrated. The dose-response relationship for Urolithin A has not been fully characterised in humans, but the available evidence suggests that the 500mg threshold is clinically relevant.
"The 500mg dose of Urolithin A was well tolerated and produced statistically significant improvements in muscle strength and endurance in middle-aged adults, alongside biomarker evidence of improved mitochondrial function." — Singh et al., Cell Reports Medicine, 2022
Who Is Most Likely to Benefit?
The NOURISH trial enrolled adults aged 40–64 who were healthy but not elite athletes. This is the population in which mitochondrial decline is beginning to manifest measurably — reduced muscle strength, lower endurance, slower recovery — but has not yet progressed to clinical dysfunction. This makes Urolithin A most relevant as a preventive and maintenance tool for active adults in this age range, rather than a therapeutic intervention for those with established metabolic conditions.
Limitations and Honest Caveats
The evidence for Urolithin A is genuinely strong by supplement standards, but several caveats are worth stating clearly. The NOURISH trial had a relatively small sample size (n=88). The study population was healthy adults, so the findings may not generalise to those with metabolic conditions. Long-term safety data beyond four months is limited. And while the mechanistic data (mitophagy activation, acylcarnitine reduction) is compelling, the translation from biomarker improvement to long-term health outcomes has not been established in humans.
These are not reasons to dismiss the evidence — they are reasons to interpret it accurately. Urolithin A at 500mg has demonstrated meaningful, statistically significant effects on muscle strength and mitochondrial biomarkers in a well-designed trial. That is more than can be said for most supplements on the market.
References
- [1]
Singh A, D'Amico D, Andreux PA, et al. (2022). Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adults. Cell Reports Medicine. PubMed →
- [2]
Andreux PA, Blanco-Bose W, Ryu D, et al. (2019). The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans. Nature Metabolism. PubMed →
- [3]
Ryu D, Mouchiroud L, Andreux PA, et al. (2016). Urolithin A induces mitophagy and prolongs lifespan in C. elegans and increases muscle function in rodents. Nature Medicine. PubMed →
Important: This article is for informational purposes only and does not constitute medical advice. Metabo Age™ is a health supplement and is not intended to diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional before making changes to your health routine.